Newly listed or thinly covered: fundamentals appear here once there is enough reported history. Prices and market cap are up to date.
Share price
₹82.05 latest close · +98.1% over the last 60 sessions
How rough has the ride been?
Drawdown from peak
Most recent volume spikes
2026-10-29: 9.5x the 50-day median, price +4.4% that day
2026-10-23: 8.4x the 50-day median, price +3.1% that day
2026-10-06: 12.1x the 50-day median, price +3.0% that day
Where does it rank among Health Technology peers?
Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Where it ranks today
- ROCE94th
- Op. margin100th
- Debt/equity ↓76th
- Cash cycle ↓29th
- P/E ↓8th
Rank history
Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.
The Health Technology sector page Watch it move against Health Technology in the Observatory
What is the price implying?
At a P/E of 108.0x, the price would imply about 36.3%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.
Fewer than six years of annual earnings are available, which is too little to measure delivered growth.
“Implied growth” is what the current price would require under our stated assumptions, not what we expect.
What prices imply across Health Technology The market-wide Expectations lists
Key figures
- Share Priceclose 9 Nov
- ₹82.05
- P/E
- 108.0x
- ROCE
- 37.0%
- Market Cap
- ₹3629 cr
- Revenue (TTM)
- ₹75 cr
- P/S
- 48.4x
- P/B
- 40.3x
- ROE
- 37.4%
- Operating Margin
- 81.0%
- Debt / Equity
- 0.1x
- Promoter Holding
- 51.0%
Balance sheet & cash
Are profits backed by cash?
Other income reliance11%Within range
Other income as a share of pre-tax profit (trailing twelve months): 11.1%. Bands: below 15%, 15% to 35%, above 35%.
Tax rate—Not enough data
Not enough reported data to compute this.
Cash conversion—Not enough data
Not enough reported data to compute this.
Free cash flow—Not enough data
Not enough reported data to compute this.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress—Not enough data
Not enough reported data to compute this.
Payable days—Not enough data
Not enough reported data to compute this.
Tap a check to see how it is measured
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
What changed?
3 events since Sep '26
- OctPriceVolume reached 28.3x its 50-day median on 2026-10-05; price +14.1% that day.
- SepPeer rankMoved into the top quartile of Health Technology on operating margin (from the 3rd quartile).
- SepPriceVolume reached 8.6x its 50-day median on 2026-09-28; price +6.3% that day.
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Monthly history4 months · 2026-08 to 2026-11
| Month | P/E | Revenue (TTM) | ROE | ROCE | Debt / Equity |
|---|---|---|---|---|---|
| 2026-11 | 108.0x | ₹75 cr | 37.4% | 37.0% | 0.1x |
| 2026-10 | 98.5x | ₹75 cr | 36.7% | 37.0% | 0.1x |
| 2026-09 | 81.7x | ₹75 cr | 36.7% | 37.0% | 0.1x |
| 2026-08 | 90.6x | ₹56 cr | 23.3% | 37.0% | 0.1x |